{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Neuroendocrine+Tumors+of+Pancreatic+Origin",
    "query": {
      "condition": "Advanced Neuroendocrine Tumors of Pancreatic Origin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 6,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:26:34.379Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00423254",
      "title": "Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian",
        "Melanoma",
        "Renal",
        "Prostate",
        "Colorectal",
        "Endometrial Carcinoma",
        "Cervical Carcinoma",
        "Testicular Cancer",
        "Thyroid Cancer",
        "Small Cell Lung Carcinoma",
        "Mesothelioma",
        "Breast Carcinoma",
        "Esophageal Carcinoma",
        "Gastric Cancer",
        "Pancreatic Carcinoma",
        "Neuroendocrine Cancer",
        "Liver Cancer",
        "Gallbladder Cancer",
        "Biliary Tract Cancer",
        "Anal Carcinoma",
        "Bone Sarcomas",
        "Soft Tissue Sarcomas",
        "Carcinoma of Unknown Origin, Primary"
      ],
      "interventions": [
        {
          "name": "PSMA/PRAME",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mannkind Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2007-02",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2010-08-03",
      "last_synced_at": "2026-05-22T05:26:34.379Z",
      "location_count": 5,
      "location_summary": "Tuscon, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 2 more",
      "locations": [
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Sparks",
          "state": "Nevada"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00423254"
    },
    {
      "nct_id": "NCT02420691",
      "title": "Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Digestive System Neuroendocrine Neoplasm",
        "Duodenal Neuroendocrine Tumor G1",
        "Functional Pancreatic Neuroendocrine Tumor",
        "Gastric Neuroendocrine Tumor",
        "Intermediate Grade Lung Neuroendocrine Neoplasm",
        "Low Grade Lung Neuroendocrine Neoplasm",
        "Nonfunctional Pancreatic Neuroendocrine Tumor",
        "Thymus Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2015-08-25",
      "completion_date": "2019-06-05",
      "has_results": true,
      "last_update_posted_date": "2020-10-30",
      "last_synced_at": "2026-05-22T05:26:34.379Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02420691"
    },
    {
      "nct_id": "NCT02955069",
      "title": "Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Well-differentiated Non-functional NET of Thoracic Origin",
        "Well-differentiated Non-functional NET of Gastrointestinal Origin",
        "Well-differentiated Non-functional NET of Pancreatic Origin",
        "Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "PDR001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 116,
      "start_date": "2017-02-14",
      "completion_date": "2020-05-13",
      "has_results": true,
      "last_update_posted_date": "2021-04-12",
      "last_synced_at": "2026-05-22T05:26:34.379Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Denver, Colorado • Tampa, Florida + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02955069"
    },
    {
      "nct_id": "NCT01177397",
      "title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Diffuse Large B-Cell Lymphoma",
        "Glioblastoma Multiforme",
        "Hepatocellular Carcinoma",
        "Non-Small Cell Lung Cancer",
        "Neuroendocrine Tumors of Non-Pancreatic Origin",
        "Hormone Receptor-Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "CC-223",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 226,
      "start_date": "2010-07-20",
      "completion_date": "2016-12-09",
      "has_results": true,
      "last_update_posted_date": "2022-12-13",
      "last_synced_at": "2026-05-22T05:26:34.379Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01177397"
    },
    {
      "nct_id": "NCT00510068",
      "title": "Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Neuroendocrine Tumors of Pancreatic Origin"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Everolimus Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 410,
      "start_date": "2007-07",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2015-07-01",
      "last_synced_at": "2026-05-22T05:26:34.379Z",
      "location_count": 24,
      "location_summary": "Mobile, Alabama • Anaheim, California • Los Angeles, California + 20 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00510068"
    },
    {
      "nct_id": "NCT03736720",
      "title": "Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Digestive System Neuroendocrine Carcinoma",
        "Locally Advanced Pancreatic Neuroendocrine Carcinoma",
        "Metastatic Digestive System Neuroendocrine Carcinoma",
        "Metastatic Pancreatic Neuroendocrine Carcinoma",
        "Refractory Digestive System Neuroendocrine Carcinoma",
        "Refractory Pancreatic Neuroendocrine Carcinoma",
        "Unresectable Digestive System Neuroendocrine Carcinoma",
        "Unresectable Pancreatic Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-06-17",
      "completion_date": "2024-08-26",
      "has_results": true,
      "last_update_posted_date": "2025-01-30",
      "last_synced_at": "2026-05-22T05:26:34.379Z",
      "location_count": 2,
      "location_summary": "Buffalo, New York • Stony Brook, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03736720"
    }
  ]
}